IDEXX Laboratories, Inc. $IDXX Stock Position Decreased by JPMorgan Chase & Co.

JPMorgan Chase & Co. cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 673,228 shares of the company’s stock after selling 196,702 shares during the quarter. JPMorgan Chase & Co.’s holdings in IDEXX Laboratories were worth $455,460,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of IDXX. Elyxium Wealth LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth $3,666,459,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of IDEXX Laboratories by 63,503.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after acquiring an additional 1,442,174 shares in the last quarter. Norges Bank bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth $332,265,000. Zurich Insurance Group Ltd FI bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $143,730,000. Finally, AustralianSuper Pty Ltd boosted its stake in shares of IDEXX Laboratories by 213.1% during the 4th quarter. AustralianSuper Pty Ltd now owns 300,197 shares of the company’s stock worth $203,092,000 after acquiring an additional 204,307 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Down 3.8%

NASDAQ:IDXX opened at $556.94 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The stock’s 50-day moving average is $563.22 and its two-hundred day moving average is $629.35. The stock has a market cap of $43.93 billion, a PE ratio of 41.01, a price-to-earnings-growth ratio of 3.17 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the previous year, the business posted $2.91 EPS. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Citigroup assumed coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.